About OregenX
OregenX is leading innovation in organoid technology, dedicated to building a new paradigm of precision medicine driven by patient-specific organoid models. We customize high-fidelity disease models and drug testing platforms to enhance clinical translation for pharmaceutical R&D and develop tools to realize personalized treatment. Currently, we have established a collection of organoids covering various organs and diseases, secured multiple core patented technologies, and are actively advancing the full value chain from drug screening to organ regeneration therapies.
Research Centers
Global Layout, Collaborative Innovation
PBC Research Center
Company Culture
Record Growth, Witness Development
Our Team
A professional team composed of internationally renowned scientists and industry elites
Core Team
Dr. Yun Xia
Chief Scientific Advisor / Co-Founder
Organoid Technology & Translational Medicine
Dr. Ximing Gong
Chief Technology Officer / Co-Founder
Gene Editing & Organoid Platform
Ms. Tina Tan
Executive Vice President / Co-Founder
Strategic Planning & Operations Management
Research & Development Team
Teamwork with Complementary Expertise
Our team brings end-to-end expertise across the organoid workflow—from cell culture and iPSC reprogramming to gene editing—working seamlessly within an integrated R&D pipeline to accelerate innovation.
Resilience Through Core Capabilities
We maintain a robust reservoir of key capabilities—including gene editing and multi-omics—to ensure uninterrupted production, seamless delivery, and resilient project continuity for our clients.
Patient-Derived Organoid Testing Platform
Using cells from individual patients, we generate organoids in the lab to rapidly test and optimize treatment strategies—accelerating the development of truly personalized therapies.